Kane Biotech Inc

Kane Biotech Inc. is a Canadian biotechnology company founded in 2001 and headquartered in Winnipeg, Manitoba, specializing in the research, development, and commercialization of anti-biofilm technologies for human and animal health applications. The company has developed a proprietary portfolio of 80+ patents focused on preventing and removing microbial biofilms, which represent a significant clinical challenge in wound care, surgical applications, and infection control. Kane Biotech's current commercial offerings include revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray, both utilizing the company's patented coactiv+® technology in a thermo-reversible gel formulation designed for optimal wound healing environments. The products are accessible through US reimbursement channels. The company is actively developing additional therapeutic solutions including coactiv+® Antimicrobial Surgical Hydrogel, DispersinB® Hydrogel, DispersinB® Acne Cleanser, and revyve® Antimicrobial Skin and Wound Cleanser. Kane Biotech also markets companion animal oral care and dermatology products (bluestem™, StrixNB®, DermaKB™) through strategic partnerships, including an exclusive North American veterinary distribution agreement with Dechra Veterinary Products LLC. The company is publicly listed on the TSX Venture Exchange (symbol: KNE) and US OTC markets (symbol: KNBIF), pursuing a royalty-based revenue model through technology licensing.